Evidence map›Paper›PMID 42591773›Full record

ArticleFrontiers in pharmacology2026

Neutrophil-hitchhiking nanoplatform overcomes blood-brain barrier to treat cerebral ischemia-reperfusion injury via ferroptosis inhibition and microglial modulation.

Shenggang Li, Bowei Yang, Kang Fan, Qingchun Mu, Hui Shen, Tan Zhang, Xun Xu, He Bai, Longguang Tang, Suji Yan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shenggang Li *Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Bowei Yang *Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Kang Fan *Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Qingchun Mu *Gaozhou People's Hospital, Guangdong Medical University, Maoming, Guangdong, China.
Hui ShenDepartment of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Tan ZhangDepartment of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Xun XuDepartment of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
He BaiCollege of Life Sciences, Mudanjiang Medical University, Mudanjiang, Heilongjiang, China.
Longguang TangDepartment of Pharmacy, Center for Regenerative and Aging Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, Zhejiang, China.
Suji YanDepartment of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Qing LanDepartment of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral ischemia reperfusion injury (CIRI) after stroke is hard to treat because the blood-brain barrier (BBB) blocks most drugs, while reperfusion triggers oxidative stress, ferroptosis, and neuroinflammation. We designed a neutrophil hitchhiking lipid nanoparticle (RKH Neu@Mino) by conjugating an RKH peptide (from Akkermansia muciniphila) onto DSPE PEG maleimide and encapsulating minocycline via microfluidic assembly. The nanoparticles specifically bind to neutrophil TLR4, allowing activated neutrophils to ferry them across the BBB and into ischemic lesions. Once there, RKH Neu@Mino suppresses ROS burst, inhibits ferroptosis, and shifts microglial polarization from pro inflammatory M1 to protective M2 phenotype, thereby mitigating CIRI. This neutrophil hitchhiking strategy offers a powerful approach to overcome the BBB delivery hurdle and treat post stroke reperfusion injury.

Indexed as

cerebral ischemia-reperfusion injuryferroptosismicroglial polarizationminocyclineneutrophil-hitchhiking

Identifiers

PMID42591773
PMCPMC13462415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.